

Composite Epitope Cd19/Cd81 Nanobodies For Modulation Of B Cell Activation

Tech ID: 34463 / UC Case 2025-187-0

INVENTION NOVELTY

VALUE PROPOSITION

TECHNOLOGY DESCRIPTION

The disclosed technology introduces nanobodies designed to modulate B cell activation with unprecedented precision. Currently in the proof-of-concept stage, this innovative approach selectively targets resting B cells, suppressing activation induced by anti-BCR antibody fragments without depleting B cells entirely. Unlike existing therapies that rely on wholesale B cell elimination and often result in significant toxicity, this invention offers a novel therapeutic strategy that finely tunes B cell sensitivity, paving the way for safer and more targeted treatments in autoimmune diseases, oncology, and other conditions involving B cell dysfunction.

APPLICATION

LOOKING FOR PARTNERS

STAGE OF DEVELOPMENT

RELATED MATERIALS

DATA AVAILABILITY

CONTACT

Hailey Zhang

hailey.zhang@ucsf.edu

tel: .



OTHER INFORMATION

CATEGORIZED AS

- **Materials & Chemicals**
- Biological
- **Medical**
- Therapeutics

RELATED CASES

2025-187-0

ADDRESS

UCSF

Innovation Ventures

600 16th St, Genentech Hall, S-272,

San Francisco, CA 94158

CONTACT

Tel:

innovation@ucsf.edu

<https://innovation.ucsf.edu>

Fax:

CONNECT

 Follow  Connect

© 2025, The Regents of the University of California

[Terms of use](#) [Privacy Notice](#)